Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis
JAMA Internal Medicine · 01.07.2025 · 185 (7) · 808
DOI: 10.1001/jamainternmed.2025.1359 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2025. Verfasst von Zhaohua Zhu und 39 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Antirheumatic Agents, Methotrexate, Osteoarthritis, Knee, Synovitis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance A recent study reported that methotrexate may reduce joint pain in patients with inflammatory hand osteoarthritis (OA). However, it remains unknown whether methotrexate has similar effects on inflammatory knee OA.
Objective
To examine whether methotrexate has symptom-relieving and disease-modifying effects for participants with knee OA and effusion-synovitis. Design, Setting, and Participants This multicenter, placebo-controlled randomized clinical trial was conducted at 11 sites in China between July 18, 2019, and January 15, 2023. Community-dwelling patients with inflammatory knee OA with effusion-synovitis on magnetic resonance imaging were included.
Interventions
Participants were randomly assigned (1:1) to receive methotrexate, up to 15 mg weekly, or placebo using block randomization, stratified by study site. Main Outcomes and Measures The primary outcomes were knee visual analog scale (VAS) pain change and effusion-synovitis maximal area change, over 52 weeks in the intention-to-treat population.
Results
Of 278 participants screened, 215 participants (mean [SD] age, 60.4 [7.4] years; 191 [89%] female) were randomized (108 to the methotrexate group; 107 to the placebo group), and 175 (81%) completed the trial. Changes in VAS pain and effusion-synovitis maximal area were not significantly different between the methotrexate and placebo group over 52 weeks (between-group difference, 0.3 mm [95% CI, −6.7 to 7.3 mm] for VAS pain; 0.1 cm 2 [95% CI, −0.8 to 1.0 cm 2 ] for effusion-synovitis maximal area). No significant between-group differences were found for any of the prespecified secondary outcomes. At least 1 adverse event occurred in approximately 32 participants (29.6%) in the methotrexate group and 26 participants (24.3%) in the placebo group. Conclusions and Relevance The results of this randomized clinical trial show that, compared to placebo, low-dose methotrexate did not reduce pain or effusion-synovitis over 52 weeks in patients with knee OA and effusion-synovitis. Trial Registration ClinicalTrials.gov Identifier: NCT03815448
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Sydney Musculoskeletal Health and Royal North Shore Hospital, Kolling Institute, University of Sydney, Sydney, Australia.
- Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical Collage Hospital, Chinese Academy of Medical Science; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Mini…
- Department of Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Zitieren
APA
Zhu, Z., Yu, Q., Leng, X., Xu, J., Ren, L., Wang, K., Huang, C., Pan, Y., Zhao, Y., Li, T., Mei, Y., Guan, M., Li, X., Zhang, Z., Wu, J., Chen, Y., Qu, Y., Zhu, X., Liao, Q., …, & Ding, C. (2025). Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis. JAMA Internal Medicine, 185(7), 808. https://doi.org/10.1001/jamainternmed.2025.1359
Vancouver
Zhu Z, Yu Q, Leng X, Xu J, Ren L, Wang K, et al. Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis. JAMA Internal Medicine. 2025;185(7):808. doi:10.1001/jamainternmed.2025.1359
BibTeX
@article{Zhu2025,
author = {Zhu, Zhaohua and Yu, Qinghong and Leng, Xiaomei and Xu, Jianhua and Ren, Limin and Wang, Kun and Huang, Cibo and Pan, Yunfeng and Zhao, Yi and Li, Tianwang and Mei, Yifang and Guan, Meihua and Li, Xiaoxia and Zhang, Zhiyi and Wu, Jing and Chen, Yingjuan and Qu, Yuan and Zhu, Xiaotong and Liao, Qiuju and Wang, Zhe and Liao, Zetao and Xi, Yang and Deng, Weiming and Wang, Kang and Zhu, Tingting and Zhang, Yuping and Gao, Lixia and Zhou, Xiaoni and Han, Weiyu and Ruan, Guangfeng and Zhang, Yan and Cao, Peihua and Gao, Peichun and Chen, Haowei and Dang, Qin and Cicuttini, Flavia M and Hunter, David J and Li, Zhanguo and Zeng, Xiaofeng and Ding, Changhai},
title = {Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis},
journal = {JAMA Internal Medicine},
year = {2025},
volume = {185},
number = {7},
pages = {808},
doi = {10.1001/jamainternmed.2025.1359}
}
EUVIMED